Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism

Running, not enrolling · Phase 2 · Has a placebo group

Conditions studied: Hypoparathyroidism

In brief

The purpose of this study is to evaluate the long-term safety and tolerability of MBX 2109 in patients with hypoparathyroidism who completed the 12-week treatment period in the Phase 2 study, MBX-2H1002.

Key facts

Study ID
NCT06531941
Run by
MBX Biosciences
People needed
60
Starts
2024-10-31
Expected to finish
2027-05-27
Last updated by the study team
2025-10-28

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.